WASHINGTON, D.C. — Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21.
The goal of the study led by Christopher Li, M.D., Ph.D., an associate member of the Epidemiology Program at the Fred Hutchinson Cancer Research Center, Seattle, was to discover and validate blood markers that could potentially be used for the early detection of breast cancer.
The study was conducted on 420 estrogen receptor-positive breast cancer patients whose blood was drawn within 17 months prior to their cancer diagnosis. The researchers validated promising markers in a similar, but completely independent set of 198 cases and controls from the Women's Health Initiative database.
One of the promising markers that was discovered and could be validated was EGFR.
EGFR levels were significantly elevated among cases compared to controls. Overall, those with the highest levels had a 2.9-fold increased risk of developing breast cancer compared to those with the lowest level.
When EGFR levels were evaluated among current users of estrogen plus progestin hormone therapy, a much larger ninefold increased risk of developing breast cancer was observed. As a single marker among current estrogen plus progestin users, EGFR had a specificity, the rate of true negative tests, of 90 percent and a sensitivity, the rate of true positive tests, of 31 percent as a breast cancer marker.
"While our results require confirmation and EGFR's performance is insufficient for it to be used as a single marker, this study is unique in that no prior studies have validated a single breast cancer early detection biomarker specimen to the degree we have here," said Li. "Our results suggest that there may indeed be detectable changes of proteins in blood within two years of making a clinical breast cancer diagnosis. Identification of these proteins could have a major impact on our ability to detect breast cancer early, when it is most treatable."
EGFR is part of the HER2 family, which has been shown to be quite important in breast cancer. Specifically, increased EGFR activity can increase the uncontrolled growth of cancer cells and EGFR is elevated in 20 percent to 81 percent of all human breast cancers. Several therapies targeting members of the HER2 family, including EGFR, have already been approved for cancer treatment.
Download interviews with cancer researchers and recordings of the teleconferences by subscribing to the AACR Scientific Podcasts via iTunes (http://www.aacr.org/itunes) or an RSS Reader (http://www.aacr.org/rss).
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 31,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowship and career development awards. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.